ClinicalTrials.gg
CompletedNCT06880848Updated Sep 24, 2025

Sonidegib in Adult Patients With Locally Advanced Basal Cell Carcinoma (laBCC) in China

A Phase 4 interventional study of Sonidegib Phosphate Capsules in Carcinoma, Basal Cell (BCC), sponsored by Jemincare. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-24.

Primary conditionCarcinoma, Basal CellRegistry: CarcinomaReclassifiedWhy we changed it
Registry
Carcinoma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Basal Cell
Why
  1. The study's listed conditions name Carcinoma, Basal Cell, a narrower term within Carcinoma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Jemincare · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Jun 2023, registered Mar 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
160
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase IV, single arm, multicenter study designed to evaluate the efficacy and safety profile of Sonidegib in chinese participants with locally advanced basal cell carcinoma (laBCC) who are not amenable to radiation therapy, curative surgery or other local therapies.

02

Conditions studied

  • Carcinoma, Basal Cell (BCC)

Browse trials for

Keywords

  • BCC
  • Basal Cell Carcinoma
03

In context

Carcinoma, Basal Cell Reclassified

389 studies on the registry are indexed under Carcinoma, Basal Cell; 69 are open to participants now.

This study's enrollment of 160 is above the median of 50 across 272 interventional studies indexed under Carcinoma, Basal Cell.

Browse Carcinoma, Basal Cell studies →

Lead sponsor

Jemincare is the lead sponsor of 37 studies on the registry; 30 are open to participants now.

Compared within Carcinoma, Basal Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Carcinoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or older.
  2. Patients with a confirmed diagnosis of laBCC that is not amenable to radiation therapy, curative surgery, or other local therapies. Patients with laBCC must have , defined as at least one lesion that can be accurately measured in at least one dimension as ≥ 10 mm, with MRI/CT scan or on color photographs.
  3. PS Score ≤ 2.
  4. Patients with adequate bone marrow, liver and renal function.
  5. Written obtained prior to any screening procedures.
  6. Patients are willing and able to comply with the scheduled visits, treatment plan, laboratory testing, study procedures, and restrictions.
  7. Females of agree to use during treatment and for 20 months following the last dose; male patients (even after vasectomy) agree to use contraception during treatment and for 8 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. Subjects in the opinion of the investigator are (e.g., organ transplant recipients, , systemic invasive within past 5 years excluding Stage I cervical cancer, ductal carcinoma in situ of the breast or CLL stage 0, graft vs. host disease, etc.).
  2. LaBCC patients with skin lesions in multiple body locations will not be considered patients. LaBCC patients with positive (histological confirmation of BCC) regional nodal disease will be considered to have metastatic disease.
  3. Poorly controlled diabetes mellitus (as per Investigator's discretion in consultation with Sponsor's medical monitor).
  4. Major surgery within 4 weeks prior to study treatment.
  5. Patients with concurrent uncontrolled medical conditions that may interfere with their participation in the study or potentially affect the interpretation of the study data.
  6. Patients unable to take oral drugs or with lack of physical integrity of the upper gastrointestinal tract or known malabsorption syndromes.
  7. Patients who have previously been treated with systemic Sonidegib or with other Hh pathway inhibitors.
  8. Patients who have neuromuscular disorders (e.g. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy).
  9. Patients who are planning on embarking on a new strenuous exercise regimen after initiation of study treatment.
  10. Have participated in other clinical trials within 4 weeks prior to the first dose of sonidegib.
  11. Have received other anti-neoplastic therapy within 4 weeks prior to study treatment.
  12. Patients who are receiving medications known to be moderate and strong inhibitors or inducers of cytochrome P450 (CYP) 3A4/5 or drugs metabolized by CYP2B6 or CYP2C9 that have narrow therapeutic index, and that cannot be discontinued before starting treatment with sonidegib. Medications that are strong /5 inhibitors should be discontinued at least 7 days and strong CYP3A/5 inducers for at least 2 weeks prior to starting treatment with sonidegib.
  13. Pregnant or nursing (lactating) women, confirmed by a positive hCG laboratory test (> 5mIU/mL).
  14. Unwilling or unable to comply with the protocol.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    Sonidegib Phosphate Capsules

    Participants will receive continuous treatment with oral administration once a day until conditions for treatment termination are met.

    Drug: Sonidegib Phosphate Capsules

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Objective response rate (ORR) is defined as the percentage of participants with a confirmed complete or partial response (CR or PR) , per modified Response Evaluation Criteria in Solid Tumors (mRECIST) as assessed by central review.

    Time frame: up to 1 year

Secondary outcomes

  1. Duration of Response (DoR)

    The DOR for a responder is defined as the time from the participant's initial CR or PR to the first date of either disease progression or death, whichever occurs first. CR, PR and PD will be determined per mRECIST by investigator and central review, respectively

    Time frame: up to 1 year

  2. Complete response rate (CRR) per central and investigator review

    CRR is defined as the percentage of participants who achieved a complete response per mRECIST

    Time frame: up to 1 year

  3. Progression-free Survival (PFS)

    PFS is defined as the time from the participant's first dose of study treatment to the first date of either disease progression or death, whichever occurs first. Disease progression will be determined per mRECIST by investigator and central review, respectively

    Time frame: up to 1 year

  4. Time to tumor response (TTR)

    TTR is defined as the time from the participant's first dose of study treatment to the date of initial CR or PR. CR and PR will be determined per mRECIST by investigator and central review, respectively.

    Time frame: up to 1 year

  5. Adverse event (AE)/Serious adverse event (SAE)/Treatment emergent adverse event (TEAE)

    Adverse events, and changes from baseline in vital signs,etc

    Time frame: up to 1 year

07

Study locations

1 site
  • Peking University First Hospital
    Beijing, China 100034, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in Aug 2025, 26 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2025
First posted
Mar 18, 2025
StartActual
Jun 21, 2023
Primary completionActual
Aug 26, 2025
CompletionActual
Aug 26, 2025
Last update
Sep 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06880848
Lead sponsor
Jemincare
Collaborators
Sun Pharmaceutical Industries Limited, Zhejiang Hangyu Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Mar 18, 2025
Start date
Jun 21, 2023
Primary completion
Aug 26, 2025
Completion
Aug 26, 2025
Last update
Sep 24, 2025

Study contacts

Hang Li
principal investigator · Peking University First Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sonidegib

Start the discussion